Skip to main content
Fig. 7 | BMC Bioinformatics

Fig. 7

From: PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients

Fig. 7

PDXGEM prediction for response to erlotinib in non-small cell lung cancer (NSCLC) patient. PDXGEM scores (a) between erlotinib-sensitive and erlotinib-resistant NSCLC cell lines, and (b) between the NSCLC patients who were responsive and those who were nonresponsive to erlotinib in the first line setting (c) Progression-free survival curves in metastatic NSCLC patients who receive erlotinib as the second-line treatment setting

Back to article page